Skip to main
IONS

Ionis Pharma (IONS) Stock Forecast & Price Target

Ionis Pharma (IONS) Analyst Ratings

Based on 20 analyst ratings
Buy
Strong Buy 45%
Buy 40%
Hold 15%
Sell 0%
Strong Sell 0%

Bulls say

Ionis Pharmaceuticals is a leader in the development of antisense technology, with a broad clinical and preclinical pipeline targeting a range of diseases. The company has a strong track record of successful partnerships, and its two independent launches in 2025 demonstrate its growing capabilities. However, Ionis has accumulated significant losses and may need to raise additional capital, posing a risk to profitability in the near term. With a current EV of ~$22.5B and a price objective of $115, the stock is a promising investment opportunity, but key risks include slower-than-expected uptake of TRYNGOLZA, regulatory setbacks, and potential spending delays hindering its 2028 cash-flow break-even target.

Bears say

Ionis Pharmaceuticals is a leading developer of antisense technology, with a broad and diverse pipeline targeting a range of diseases. However, the company's modest salesforce and focus on rare diseases may limit its ability to reach a significant number of patients and generate strong revenue. Additionally, recent approvals and upcoming launches may not meet previous peak-sales estimates due to potential challenges in patient identification and administration hurdles for certain drugs.

Ionis Pharma (IONS) has been analyzed by 20 analysts, with a consensus rating of Buy. 45% of analysts recommend a Strong Buy, 40% recommend Buy, 15% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Ionis Pharma and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Ionis Pharma (IONS) Forecast

Analysts have given Ionis Pharma (IONS) a Buy based on their latest research and market trends.

According to 20 analysts, Ionis Pharma (IONS) has a Buy consensus rating as of Sep 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $90, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $90, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Ionis Pharma (IONS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.